Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Other Accumulated Expenses (2019 - 2025)

Historic Other Accumulated Expenses for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $2.1 million.

  • Nurix Therapeutics' Other Accumulated Expenses fell 786.81% to $2.1 million in Q4 2025 from the same period last year, while for Nov 2025 it was $2.1 million, marking a year-over-year decrease of 786.81%. This contributed to the annual value of $2.1 million for FY2025, which is 786.81% down from last year.
  • According to the latest figures from Q4 2025, Nurix Therapeutics' Other Accumulated Expenses is $2.1 million, which was down 786.81% from $1.7 million recorded in Q3 2025.
  • In the past 5 years, Nurix Therapeutics' Other Accumulated Expenses ranged from a high of $2.7 million in Q1 2025 and a low of $551000.0 during Q1 2022
  • Moreover, its 5-year median value for Other Accumulated Expenses was $1.0 million (2023), whereas its average is $1.2 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 27271.21% in 2022, then plummeted by 5003.33% in 2023.
  • Quarter analysis of 5 years shows Nurix Therapeutics' Other Accumulated Expenses stood at $659000.0 in 2021, then soared by 128.07% to $1.5 million in 2022, then plummeted by 50.03% to $751000.0 in 2023, then surged by 202.93% to $2.3 million in 2024, then dropped by 7.87% to $2.1 million in 2025.
  • Its Other Accumulated Expenses was $2.1 million in Q4 2025, compared to $1.7 million in Q3 2025 and $1.0 million in Q2 2025.